CSIQ

CSIQ screens optically cheap at 0.2x sales and a $1.04B market cap, but the fundamentals are deteriorating in a way the multiple alone can't fix. FY2025 revenue fell 6.6% to $5.60B — the second straight year of contraction from the $7.61B FY2023 peak — and the company swung from $274M of net income in FY2023 to a $104M loss in FY2025 (-388.8% YoY). Operating margin collapsed to 0.8% and ROE turned negative at -3.7%, so the business is now destroying shareholder capital while competing in a commoditized module market against heavily-subsidized Chinese peers.

The balance sheet is the bigger problem. Liabilities-to-equity has reached 3.88x, long-term debt jumped 30.5% YoY to $6.01B, and the current portion of debt grew 27.5% to $2.39B — against only $1.37B of cash (which itself fell 19.5% YoY). Meanwhile operating cash flow was -$253M and capex ran at $962M, meaning the company is financing a large free-cash-flow deficit with more debt at a moment when its own equity base is shrinking. That is the classic setup for either dilutive equity issuance or a forced asset sale, neither of which is friendly to today's holder.